Data / Drug companies / Rocuronium bromide
Rocuronium bromide: 25 companies and 67 products in the FDA NDC directory
Rocuronium bromide is listed in the FDA National Drug Code Directory by 25 companies, with 67 products in commercial distribution. 60 of the products (89.6%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, solution; injection; solution, and the newest product started marketing on September 18, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 25
- Products
- 67
- Generic (ANDA) products
- 60 (89.6%)
- Application numbers
- 17
- Routes
- Intravenous
- Brand names
- Rocuronium
- openFDA record search
- api.fda.gov
Companies that list rocuronium bromide
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| HF Acquisition Co LLC, DBA HealthFirst | 8 | injection, solution; injection | Generic drugs (ANDA) | July 17, 2023 |
| Medical Purchasing Solutions, LLC | 8 | injection; injection, solution | Generic drugs (ANDA) | October 3, 2024 |
| Hospira, Inc. | 6 | injection, solution | Generic drugs (ANDA) | August 28, 2023 |
| Fresenius Kabi USA, LLC | 5 | injection, solution | New drug applications (NDA) | October 11, 2023 |
| Baxter Healthcare Corporation | 4 | injection; injection, solution | Generic drugs (ANDA) | September 18, 2026 |
| Meitheal Pharmaceuticals Inc. | 4 | injection | Generic drugs (ANDA) | May 8, 2023 |
| ProPharma Distribution | 3 | injection, solution; injection | Generic drugs (ANDA) | October 3, 2024 |
| Be Pharmaceuticals Inc. | 2 | injection, solution | Generic drugs (ANDA) | July 12, 2023 |
| Caplin Steriles Limited | 2 | injection, solution | Generic drugs (ANDA) | October 3, 2024 |
| Civica, Inc. | 2 | injection | Generic drugs (ANDA) | December 16, 2020 |
| Eugia US LLC | 2 | injection, solution | Generic drugs (ANDA) | April 12, 2017 |
| Fresenius Kabi USA, LLC | 2 | injection, solution | Generic drugs (ANDA) | December 13, 2009 |
| Fresenius Kabi USA, LLC | 2 | injection, solution | New drug applications (NDA) | October 11, 2023 |
| Gland Pharma Limited | 2 | injection | Generic drugs (ANDA) | May 18, 2018 |
| Hikma Pharmaceuticals USA Inc. | 2 | injection | Generic drugs (ANDA) | April 30, 2017 |
| Lifestar Pharma LLC | 2 | injection | Generic drugs (ANDA) | May 29, 2025 |
| Shandong New Time Pharmaceutical Co., Ltd. | 2 | injection, solution | Generic drugs (ANDA) | July 12, 2024 |
| Solco Healthcare US, LLC | 2 | injection | Generic drugs (ANDA) | July 25, 2021 |
| B. Braun Medical Inc. | 1 | injection | New drug applications (NDA) | May 21, 2026 |
| Mylan Institutional LLC | 1 | injection | Generic drugs (ANDA) | February 6, 2012 |
| Phlow Corporation | 1 | injection, solution | Generic drugs (ANDA) | February 8, 2022 |
| Sagent Pharmaceuticals | 1 | injection | Generic drugs (ANDA) | October 15, 2023 |
| Sandoz Inc | 1 | injection, solution | Generic drugs (ANDA) | December 5, 2008 |
| Steriscience Specialties Private Limited | 1 | injection, solution | Generic drugs (ANDA) | November 30, 2024 |
| XGen Pharmaceuticals DJB, Inc. | 1 | solution | Generic drugs (ANDA) | December 1, 2012 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 39 | 58.2% |
| Injection | 25 | 37.3% |
| Solution | 3 | 4.5% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 60 | 89.6% |
| New drug applications (NDA) | 7 | 10.4% |
Pharmacologic classes
| Class | Products |
|---|---|
| Nondepolarizing Neuromuscular Blocker | 67 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.